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Abstract
Background: Melanomas are highly malignant and have high metastatic potential; hence, there is a need for new
therapeutic strategies to prevent cell metastasis. In the present study, we investigated whether statins inhibit tumor
cell migration, invasion, adhesion, and metastasis in the B16BL6 mouse melanoma cell line.
Methods: The cytotoxicity of statins toward the B16BL6 cells were evaluated using a cell viability assay. As an
experimental model, B16BL6 cells were intravenously injected into C57BL/6 mice. Cell migration and invasion were
assessed using Boyden chamber assays. Cell adhesion analysis was performed using type I collagen-, type IV
collagen-, fibronectin-, and laminin-coated plates. The mRNA levels, enzyme activities and protein levels of matrix
metalloproteinases (MMPs) were determined using RT-PCR, activity assay kits, and Western blot analysis,
respectively; the mRNA and protein levels of vary late antigens (VLAs) were also determined. The effects of statins
on signal transduction molecules were determined by western blot analyses.
Results: We found that statins significantly inhibited lung metastasis, cell migration, invasion, and adhesion at
concentrations that did not have cytotoxic effects on B16BL6 cells. Statins also inhibited the mRNA expressions and
enzymatic activities of matrix metalloproteinases (MMPs). Moreover, they suppressed the mRNA and protein
expressions of integrin a2, integrin a4, and integrin a5 and decreased the membrane localization of Rho, and
phosphorylated LIM kinase (LIMK) and myosin light chain (MLC).
Conclusions: The results indicated that statins suppressed the Rho/Rho-associated coiled-coil-containing protein
kinase (ROCK) pathways, thereby inhibiting B16BL6 cell migration, invasion, adhesion, and metastasis. Furthermore,
they markedly inhibited clinically evident metastasis. Thus, these findings suggest that statins have potential clinical
applications for the treatment of tumor cell metastasis.
Background
Metastatic melanoma is a highly aggressive, often fatal
malignancy, which exhibits resistance to all the current
therapeutic approaches. At the time of diagnosis, about
20% of melanoma patients already have metastatic dis-
ease. Once metastasis has occurred, the overall median
survival is only 6-9 months [1]. The recent increase in
the incidence of melanoma has brought to light the
need for novel molecular approaches for treating mela-
noma metastasis [2].
Metastasis is a complex process that is dependent on
the capacity of cancer cells to invade and migrate into
adjoining cells and tissues, and proliferate into tumor
growths [3,4]. Consistent with this definition, cell inva-
sion and migration are highly related to the activity of
matrix metalloproteinases (MMPs) that regulate many
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growth, migration, and extracellular matrix (ECM)
degradation [5]. Notably, MMP-1, MMP-2, MMP-9, and
MMP-14 (MT1-MMP) have been implicated in the
invasion and metastatic processes in several cancers
[6,7].
Cell adhesion is an essential process of metastatic cas-
cades. Integrin-mediated cell adhesion affects the forma-
tion of focal adhesions, which are multimolecular
structures that enable firm adhesion of cells. Integrins
are a family of heterodimeric cell-surface adhesion
receptors composed of a and b subunits [8,9]. Each
integrin binds specific ECM components to aggregates
present in the cell membrane. Changes in the structure
and/or expression of integrins are frequently associated
with malignant transformation and tumor progression
[8,10]. It has been reported that in highly metastatic
melanomas, the expression of ECM receptors such as
a2b1 integrin, a3b1 integrin and a4b1 integrin is gener-
ally up-regulated [11,12].
The mevalonate metabolic pathway is essential for
membrane formation and the isoprenylation of a num-
ber of small GTPases, which are involved in cell growth
and differentiation. The products of this pathway
include farnesyl pyrophosphate and geranylgeranyl pyro-
phosphate, which modify and direct small GTPases to
their site of action [13,14]. The protein targets for iso-
prenylation include small G proteins, which require
post-translational modification to undergo a series of
changes that lead to their attachment to the plasma
membranes and make them fully functional. The farne-
sylated Ras proteins are associated with the mitogenic
signal transduction that occurs in response to growth
factor stimulation [15]. The geranylgeranylated proteins
of the Rho family include RhoA, Rac1, and Cdc42; these
proteins regulate signal transduction from receptors in
the membrane in a variety of cellular events related to
cell adhesion to the ECM, cell morphology, cell motility,
and invasion, thereby acting as molecular switches in
the cell [16].
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase is considered to be the major regulatory
enzyme of mevalonate metabolic pathway. HMG-CoA
reductase inhibitors (statins) are reversible inhibitors of
the rate-limiting step in cholesterol biosynthesis [17].
Most experimental studies using statins have focused on
the effects of drugs on tumor cell growth in vitro and in
vivo [18-21]. However, limited information is available
on the effects of these agents on tumor cell invasion,
adhesion, and metastasis [22-25]. Furthermore, there are
no detailed reports on the exact mechanism of the inhi-
bitory effects of statins on invasion, adhesion, and
metastasis of tumor cells. Statins are widely used clini-
cally; therefore, if they are found to inhibit tumor
metastasis, they could have potential use in the future.
In the present study, we have investigated the mechan-
isms by which statins inhibit tumor cell migration, inva-
sion, adhesion, and metastasis in the mouse melanoma
cell line B16BL6.
Materials and methods
Materials
Simvastatin was purchased from Wako (Osaka, Japan),
and fluvastatin was purchased from Calbiochem (San
Diego, CA, USA). These reagents were dissolved in
dimethyl sulfoxide (DMSO) and filtered through 0.45-
μm syringe filters (IWAKI GLASS, Japan). The dissolved
regents were resuspended in phosphate-buffered saline
(PBS; pH 7.4) and used in the various assays described
below.
Y27632, a Rho-associated coiled-coil-containing pro-
tein kinase (ROCK) inhibitor, was purchased from
Wako and dissolved in DMSO. The dissolved regent
was resuspended in PBS and filtered through syringe fil-
ters before use.
Cell culture
B16 melanoma BL6 cells (B16BL6 cells) were supplied
by Dr. Inufusa (Kinki University, Osaka, Japan) and cul-
tured in RPMI 1640 medium (Sigma) supplemented
with 10% fetal calf serum (FCS) (Gibco, Carlsbad, CA,
USA), 100 μg/ml penicillin (Gibco), 100 U/ml strepto-
mycin (Gibco), and 25 mM HEPES (pH 7.4; Wako,
Tokyo, Japan) in an atmosphere containing 5% CO2.
Mice
Female C57BL/6J mice (age, 8 weeks) were purchased
from Shimizu Laboratory Animals (Kyoto, Japan). The
mice were maintained in a pathogen-free environment
at 25°C under controlled lighting (12-h light/12-h dark
cycles) and allowed free access to water and food pellets.
All animal studies were performed in accordance with
the Recommendations for Handling of Laboratory Ani-
mals for Biomedical Research compiled by the Commit-
tee on Safety and Ethical Handling Regulations for
Laboratory Animal Experiments, Kinki University. The
ethical procedures followed met the requirements of the
UKCCCR guidelines (1998).
Experimental metastasis of tumor cells
B16BL6 cells (1 × 10
5 cells in 0.2 ml) were injected into
the tail vein of syngeneic C57BL/6J mice, after viable
cells were counted with trypan blue exclusion. The mice
were anesthetized with pentobarbital and sacrificed at
14 d after the cell injection. Subsequently, their lungs
were excised and fixed in a neutral-buffered formalde-
hyde solution. Nodules visible as black forms in the
lungs were then enumerated.
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metastasis of tumor cells
B16BL6 cells (1 × 10
5 cells in 0.2 ml) were injected into
the tail vein of syngeneic C57BL/6J mice, after viable
cells were counted with trypan blue exclusion. In the
experiment, the B16BL6-inoculated mice were randomly
divided into 3 groups comprising 9 mice each. For 14 d
from the day of inoculation, 0.1% DMSO was adminis-
tered orally to the first group, which was defined as the
control group, whereas simvastatin or fluvastatin (10
mg/kg/d) was administered to the remaining 2 groups.
Cell viability
Cell viability was assessed by the tetrazolium dye proce-
dure by using a TetraColor ONE assay kit (Seikagaku,
Tokyo, Japan). B16BL6 cells (2000 cells/well) were pla-
ted in 96-well plates and incubated with 0.01, 0.05, 0.1,
and 0.5 μM fluvastatin, or 0.1, 0.5, 1, and 5 μMs i m v a s -
tatin for 1, 3, or 5 d. The absorbance values of the wells
were measured at 492 nm by using a microplate reader
(SK601; Seikagaku).
Western blotting
B16BL6 cells treated under various conditions were
lysed with a lysis buffer (20 mM Tris-HCl [pH 8.0], 150
mM NaCl, 2 mM ethylenediaminetetraacetic acid
[EDTA], 100 mM NaF, 1% NP-40, 1 μg/ml leupeptin, 1
μg/ml antipain, and 1 mM phenylmethyl sulfonyl fluor-
ide [PMSF]), and the protein concentrations of the
resulting cell lysates were determined using a BCA pro-
tein assay kit (Pierce, Rockford, IL, USA). The mem-
brane fraction of B16BL6 cells was extracted using the
ProteoExtract Native Membrane Protein Extraction Kit
(Calbiochem). A 40-μg protein aliquot of each extract
was fractionated by electrophoresis in a sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) and transferred
to a polyvinylidene fluoride (PVDF) membrane (Amer-
sham, Arlington Heights, IL, USA). The membranes
were blocked with a solution containing 3% skim milk,
and then incubated overnight at 4°C with each of the
following antibodies: anti-phospho-LIMK antibody, anti-
LIMK antibody, anti-phospho-MLC antibody (Cell Sig-
naling Technology, Beverly, MA, USA), anti-MMP-14
antibody (Calbiochem), anti-a2 integrin antibody (Che-
micon Int. Inc., California, USA), anti-a4 integrin anti-
body (SantaCruz Biotechnology, CA, USA), anti-a5
integrin antibody (SantaCruz Biotechnology), and anti-
Rho antibody (Upstate Biology, Charlottesville, VA,
USA). Subsequently, the membranes were incubated for
1 h at room temperature with anti-rabbit IgG sheep
antibody coupled to horseradish peroxidase (Amer-
sham). Reactive proteins were visualized using a chemi-
luminescence kit (Amersham) according to the
manufacturer’s instructions. Mouse anti-b-actin
monoclonal antibody (Sigma) was used as the primary
antibody (internal standard) for detecting b-actin
protein.
Reverse transcription-polymerase chain reaction
Total RNA was isolated using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA), and a 1-μg aliquot of purified
total RNA was subjected to reverse transcription-poly-
merase chain reaction (RT-PCR) analysis using a Super-
Script First-Strand Synthesis System for RT-PCR
(Invitrogen). The resulting cDNAs were used as a tem-
plate for PCR amplification to generate products corre-
sponding to the mRNAs encoding various gene
products. Each PCR reaction mixture contained cDNA,
dNTP mix (Takara Biomedical, Shiga, Japan), 10× PCR
buffer (Takara Biomedical), and Pyrobest (Takara Bio-
medical). The cDNAs were amplified under the follow-
ing cycling conditions: For GADPH, the cDNA was
amplified with 30 cycles of denaturation at 94°C for 0.5
min, annealing at 60°C for 0.5 min, and extension at 72°
C for 0.5 min; and for MMP-1, MMP-2, MMP-9, MMP-
14, integrin a1,i n t e g r i na2,i n t e g r i na3,i n t e g r i na4,
integrin a5, and integrin a6, the cDNA was amplified
with 35 cycles of denaturation at 94°C for 1 min,
annealing at 55°C for 1 min, and extension at 72°C for 2
min were carried out. All PCR amplifications were per-
formed using a DNA thermal cycler (Takara PCR ther-
mal cycler MP; Takara Biomedical). The following
primers were used: MMP-1, 5′-CGA CTC TAG AAA
CAC AAG AGC AAG A-’3( 5 ′-primer) and 5′-AAG
GTT AGC TTA CTG TCA CAC GCT T-3′ (3′-primer);
MMP-2, 5′-TGT GTC TTC CCC TTC ACT TT-’3( 5 ′-
primer) and 5′-GAT CTG AGC GAT GCC ATC AA-3′
(3′-primer); MMP-9, 5′-AGG CCT CTA CAG AGT
CTT TG-3′ (5′-primer) and 5′-CAG TCC AAC AAG
AAA GGA CG-3′ (3′-primer); MMP-14, 5′-ACA CCC
TTT GAT GGT GAA GG-3′ (5′-primer) and 5′-TCG
GAG GGA TCG TTA GAA TG-3′ (3′-primer); integrin
a1,5 ′-CCT GTA CTG TAC CCA ATT GGA TGG-3′
(5′-primer) and 5′-GTG CTC TTA TGA AAG TCG
GTT TCC-3′ (3′-primer); integrin a2,5 ′-TCT GCG
T G TG G AC A TC A GT T TG G A - 3 ′ (5′-primer) and 5′-
GAT AAC CCC TGT CGG TAC TTC TGC-3′ (3′-pri-
mer); integrin a3,5 ′-ATT GAC TCA GAG CTG GTG
GAG GAG-3′ (5′-primer) and 5′-TAC TTG GGC ATA
ATC CGG TAG TAG-3′ (3′-primer); integrin a4,5 ′-
GTC TTC ATG CTC CCA ACA GC-3′ (5′-primer) and
5′-ACT TCT GAC GTG ATT ACA GGA AGC-3′ (3′-
primer); integrin a5,5 ′-CTG CAG CTG CAT TTC
CGA GTC TGG-3′ (5′-primer) and 5′-GAA GCC GAG
CTT GTA GAG GAC GTA-3′ (3′-primer); integrin a6,
5′-GAG GAA TAT TCC AAA CTG AAC TAC-3′ (5′-
primer) and 5′-GGA ATG CTG TCA TCG TAC CTA
GAG-3′ (3′- p r i m e r ) ;G A P D H ,5 ′-ACT TTG TCA AGC
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TAT TG-3′ (3′-primer). The PCR products were mixed
with bromophenol blue (loading buffer) and separated
by electrophoresis in a 2% agarose gel in Tris-acetate-
EDTA (TAE) buffer. After staining with ethidium bro-
mide, the bands obtained after PCR were visualized
under ultraviolet light and recorded with a Coolsaver
(ATTO, Tokyo, Japan).
In vitro migration and invasion assays
Migration was analyzed by Boyden chamber assays using
Falcon cell culture inserts (8.0 μm pore size; Becton
Dickinson, Franklin Lakes, NJ, USA). Invasive properties
of the cells were analyzed using Falcon cell culture inserts
covered with 50 μg of Matrigel (Becton Dickinson) per
filter. Adjusted viable cells concentration was counted
with trypan blue exclusion. The upper and lower cham-
bers of the inserts for both assays were filled with 500 μl
of a cell and drug suspension (1 × 10
4 cells) and 1 ml of
NIH/3T3 fibroblast-conditioned medium, respectively.
After incubation for 24 h, the remaining cells in the
upper layer were swabbed with cotton, and the cells that
had penetrated the lower layer were fixed with 95% etha-
nol and extracted for hematoxylin staining. The cells that
passed through each 8-μm pore of the culture insert were
counted under a light microscope.
Collagenase activities
Type I and type IV collagenase activities were measured
using the appropriate assay kits (YAGAI Corp., Yama-
gata, Japan). Type I or type IV collagen was briefly
labeled with fluorescein isothiocyanate (FITC) and
added to the reaction mixture; this was followed by sub-
sequent incubation for 2 h at 37°C (for type I collage-
n a s e ;M M P - 1 )o r4 2 ° C( f o rt y p eI Vc o l l a g e n a s e s ;M M P -
2 and MMP-9). The remaining substrate was precipi-
tated with ethanol and extracted after centrifugation at
8000 rpm for 10 min. The release of denatured collagen
into the supernatant of each reaction mixture was mea-
sured by the intensity of the fluorescence emission at
520 nm following excitation at 495 nm.
Adhesion assay
For this assay, 24-well tissue culture plates were coated
with collagen I, collagen IV, fibronectin, or laminin
(Becton Dickinson Biosciences) and incubated at 37°C
in a 5% CO2 atmosphere for 1 h. Immediately before
use, the coated wells were overlaid with 1% bovine
serum albumin (BSA) for 30 min, washed 5 times with
PBS, and dried for 30 min at room temperature in the
tissue culture hood. Adjusted viable cells concentration
was counted with trypan blue exclusion. The cells were
loaded into individual wells (1 × 10
4 cells/well) and
incubated for 30 min at 37°C in a 5% CO2 atmosphere.
Nonadherent cells were aspirated and washed 3 times.
Adherent cells were counted under an Olympus micro-
scope (Olympus, Tokyo, Japan) at 20× magnification.
The measurements were conducted in triplicate for each
experimental group.
Statistical analysis
All the results were expressed as the mean ± SD of sev-
eral independent experiment values. Multiple compari-
sons of the data were performed by analysis of variance
(ANOVA) with Dunnett’st e s t .P values < 1% were
regarded as significant.
Results
Cytotoxicity toward B16BL6 cells
Cell viability of B16BL6 cells was assessed in the pre-
sence of fluvastatin (range, 0.01-0.5 μM) or simvastatin
(range, 0.1-5 μM) in order to examine the cytotoxic
effects of fluvastatin or simvastatin. We determined the
cell survival rate, which was defined as the number of
living cells as compared with the number of live control
cells (0.1% DMSO-treated). The cell survival rates were
calculated 1, 3, and 5 d after fluvastatin or simvastatin
exposure. In the presence of 0.01, 0.05, 0.1, and 0.5 μM
fluvastatin, the cell survival rates were 99.39%, 94.74%,
81.59%, and 50.77%, respectively, on day 5 (Figure 1A).
In the presence of 0.1, 0.5, 1, and 5 μM simvastatin, the
cell survival rates were 105.80%, 89.16%, 84.84%, and
75.52%, respectively, on day 5 (Figure 1B). A decrease in
the number of B16BL6 cells was observed at day 5 after
the administration of 0.1 and 0.5 μM fluvastatin or 0.5,
1, and 5 μM simvastatin (P <0 . 0 1 ) .O nt h eb a s i so f
these results, we selected 0.05 μMa n d0 . 1μMa st h e
concentrations at which fluvastatin and simvastatin,
respectively, were not cytotoxic toward B16BL6 cells.
Inhibitory effect of statins on lung metastasis in B16BL6
cells
Mice injected with tumor cells following a 3-d pretreat-
ment with 0.05 μM fluvastatin or 0.1 μM simvastatin dis-
played visible lung nodules at 14 d after the injection.
The numbers of pulmonary nodules following pretreat-
ment with 0.1% DMSO (control cells), 0.1 μMs i m v a s t a -
tin, and 0.05 μM fluvastatin were 452.6 ± 40.8, 257.6 ±
45.6, and 256.0 ± 33.9, respectively (P < 0.01, Figure 1C).
Statins inhibit tumor cell migration and invasion
Cell migration and invasion are critical processes in tumor
metastasis. We investigated the effects of statins on
B16BL6 cell migration and invasion by the Boyden cham-
ber and Matrigel invasion chamber assays, respectively.
The number of B16BL6 cells migrating and invading
through the chambers was significantly decreased by pre-
treatment of the cells with statins (P < 0.01, Figure 1D, E).
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MMP-2, MMP-9, and MMP-14 in B16BL6 cells
W ef o u n dt h a ts t a t i n sh a da ni n h i b i t o r ye f f e c to ni n v a -
s i o n ;t h i sp r o m p t e du st oe x a m i n ei t se f f e c t so nt h e
expression of MMP-1, MMP-2, MMP-9, and MMP-14.
First, we examined whether statins could inhibit the
expression of these MMP mRNAs. Administration of
statins markedly inhibited the MMP mRNA expression
of all the MMPs (Figure 2A). Next, we investigated
whether type I and type IV collagenase activities and
MMP-14 protein production were inhibited in B16BL6
cells that were pretreated with statins. After statins were
administered, the type I and type IV collagenase activ-
ities, as well as the level of MMP-14 protein, were
markedly reduced in B16BL6 cells (Figure 2B-D).
Inhibitory effect of statins on the adhesion of B16BL6
cells to type I collagen, type IV collagen, fibronectin, and
laminin
The adhesion of tumor cells to ECM components is an
integrin-dependent process. The ability of tumor cells to
adhere to and interact with different components of the
ECM is a prerequisite for cell migration and cell inva-
sion into the basement membrane. We investigated the
effect of statins on the adhesion of B16BL6 cells to type
I and type IV collagen, fibronectin, and laminin. We
observed that the number of cells that adhered to type I
collagen, type IV collagen, fibronectin, and laminin were
significantly decreased in the presence of statins as com-
pared to that in the 0.1% DMSO-treated cultures (con-
trol) (P < 0.01, Figure 3A-D).
Suppression of integrin a2, integrin a4, and integrin a5
mRNA and protein expression by statins
To elucidate the effect of statins on cell adhesion to
ECM components, the mRNA expression of a integrins
was assessed by RT-PCR. As shown in Figure 3E, statins
suppressed the mRNA expression of integrin a2,i n t e g -
rin a4, and integrin a5 in the B16BL6 cells. There was
no substantial change in the level of integrin a1, integrin
a3, and integrin a6 mRNA expressions in the statins-
treated cells compared with that in the control cells
Figure 1 Inhibitory effect of statins on tumor cell metastasis, migration, and invasion. (A, B) Determination of the statin concentrations
suitable for administration to B16BL6 cells. The cells were incubated in 96-well plates for 24 h and then treated with 0.01-0.5 μM fluvastatin, or
0.1-5 μM simvastatin. After 1, 3, or 5 d, cell viability was quantified by WST-8 assays. The results are representative of 5 independent experiments.
(C) B16BL6 cells, which had been pretreated with 0.05 μM fluvastatin or 0.1 μM simvastatin for 3 d, were injected into the tail veins of syngeneic
C57BL/6J mice. After 14 d, visible nodules that had metastasized to the lungs were counted. The results are expressed as the mean ± SD of 9
mice. (D, E) B16BL6 cells were pretreated with 0.05 μM fluvastatin or 0.1 μM simvastatin for 3 d, after which cells were seeded into the upper
compartments of chambers. (D) Migration was analyzed by Boyden chamber assays using Falcon cell culture inserts. (E) Invasive properties were
analyzed using Falcon cell culture inserts covered with 50 μg of Matrigel per filter. For both assays, the lower chambers contained conditioned
media from NIH/3T3 cells cultured for 24 h, which was used as a chemoattractant. After incubation for 24 h, the cells invading the lower surface
were counted microscopically. The results are representative of 5 independent experiments.
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the protein expression of integrin a2,i n t e g r i na4,a n d
integrin a5 was actually inhibited in the B16BL6 cells
when statins were administered; we observed that after
the administration of statins, the protein expressions of
integrin a2,i n t e g r i na4, and integrin a5 were signifi-
cantly reduced (Figure 3F).
Inhibitory effects of statins on the Rho signaling pathway
To demonstrate whether statins inhibit the functions of
Rho by suppressing their prenylation, the protein sam-
ples were subjected to a standard western blot assay to
detect the presence of small GTPases in both the mem-
brane and cytoplasm lysates of B16BL6 cells incubated
with or without statins. The membrane localization of
Rho proteins showed a significant decrease in statin-
treated cells compared to the control cells (0.1%
DMSO-treated). In contrast, the cytoplasmic localization
of Rho proteins showed an increase in the reagent-
treated cells compared to the control cells (0.1%
DMSO-treated) (Figure 4A). Moreover, statins inhibited
the expression of phosphorylated LIMK and MLC, as
downstream of Rho. Thus, these results suggest that the
Rho signaling pathway was inhibited by statins in our
experiment model.
Inhibitory effect of Y27632 on lung metastasis in B16BL6
cells
The results described so far have shown that the inhibi-
tory effect of statins on lung metastasis is exerted via
the inhibition of Rho prenylation. We next administered
Y27632, a ROCK inhibitor, to B16BL6 cells in order to
determine whether suppression of the Rho/ROCK path-
way would cause the inhibition of lung metastasis. As
observed in the case of statins, administration of Y27632
sufficiently inhibited lung metastasis (P < 0.01, Figure
4B). In addition, Y27632 decreased the expression of
phosphorylated LIMK and MLC (Figure 4C). These
Figure 2 Inhibitory effects of statins on the mRNA expressions and protein activities of MMPs. B16BL6 cells were treated with 0.05 μM
fluvastatin or 0.1 μM simvastatin for 3 d. (A) Equal amounts of total RNA were reverse-transcribed to generate cDNAs that were used for PCR
analysis of the mRNA expressions of MMPs in B16BL6 cells. (B, C) Activities of (B) type I collagenase (MMP-1) and (C) type IV collagenases (MMP-2
and MMP-9) in B16BL6 cells. Conditioned media were harvested, and the type I and type IV collagenase activities were measured by FITC-
conjugated type I and type IV collagen breakdown assays, respectively. The results are representative of 5 independent experiments. (D) Image
showing a western blot of the MT1-MMP protein expression.
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Page 6 of 11Figure 3 Effect of statins on B16BL6 cell adhesion to ECM components. B16BL6 cells, which had been treated with 0.05 μM fluvastatin or
0.1 μM simvastatin for 3 d, were incubated with (A) type I collagen-, (B) type IV collagen-, (C) fibronectin-, or (D) laminin-coated plates for 30
min at 37°C in an atmosphere containing 5% CO2. The results are representative of 5 independent experiments. (E) Image showing the results of
RT-PCR analysis of integrins mRNA. B16BL6 cells were treated with 0.05 μM fluvastatin or 0.1 μM simvastatin. After 3 d, equal amounts of RNA
were reverse-transcribed to generate cDNA, which was used for PCR analysis of integrins mRNA expression in B16BL6 cells. (E) Image showing
western blot of the integrin a2, integrin a4, and integrin a5 proteins. Whole-cell lysates were generated and immunoblotted with antibodies
against integrin a2, integrin a4, integrin a5, and b-actin (internal standard).
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Page 7 of 11Figure 4 Statins specifically suppress the Rho/ROCK pathway. (A) B16BL6 cells were treated with 0.05 μM fluvastatin or 0.1 μM simvastatin
for 3 d. Rho expression was determined by immunoblotting analysis of the membrane and cytoplasmic fractions by using the anti-Rho
antibody. The expression of phosphorylated LIMK and MLC was determined by immunoblotting analysis of the whole-cell lysate using
phosphorylated LIMK (phospho-LIMK) and phosphorylated MLC (phospho-MLC). (B) B16BL6 cells, which had been treated with 75 μM Y27632 for
3 d, were injected into the tail veins of syngeneic C57BL/6J mice. After 14 d, visible nodules that metastasized to the lung were counted. The
results are expressed as the means ± S.D. of 9 mice. (C) B16BL6 cells were treated with 75 μM Y27632 for 3 d. The expression of phosphorylated
LIMK and MLC was determined by immunoblotting analysis of the whole-cell lysate using phosphorylated LIMK (phospho-LIMK), phosphorylated
MLC (phospho-MLC), and b-actin (internal standard).
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by suppressing the Rho signaling pathway.
Inhibitory effect of oral administration of statins on
tumor metastasis
To determine whether oral administration of statins
would inhibit metastasis, we investigated their effect on
the development of metastasis in C57BL6/J mice. The
results indicated that statins significantly inhibited lung
metastasis (P < 0.01, Figure 5) when administered orally.
Discussion
In the present study, we have demonstrated that statins
inhibit cell migration, invasion, adhesion, and metastasis
through the suppression of the Rho/ROCK pathway in
mouse melanoma B16BL6 cells. It has been reported
that overexpression of RhoA increases tumor metastasis
in human melanomas [26]. It has also been reported
that the overexpression of RhoC enhances metastasis,
whereas dominant-negative expression of RhoC inhibits
metastasis [27]. In addition, statins have been reported
to inhibit tumor cell migration and invasion through the
suppressing geranylgeranylation of Rho in breast and
colon cancer cell lines [28,29]. These findings suggest
that statins may bring about their anti-metastatic effects
by inactivating the Rho/ROCK pathway.
Cell migration is known to be required for tumor
metastasis. In this study, we showed that statins inhib-
ited the migration of B16BL6 cells. It has been reported
that YM529/ONO-5920 and zoledronate, nitrogen-con-
taining bisphosphonates, inhibited hepatocellular carci-
noma and osteosarcoma cell migration by suppressing
GGPP biosynthesis [30,31]. Collectively, the findings
suggest that the inhibition of GGPP biosynthesis plays
an important role in the suppression of B16BL6 cell
migration by statins.
Matrix metalloproteinases (MMPs) and zinc-depen-
dent endopeptidases are a family of structurally related
zymogens that are capable of degrading the ECM,
including the basement membrane. They are presumed
to be critically involved in tumor invasion and metasta-
sis [32]. In melanomas, higher levels of MMP-1, MMP-
2, MMP-9, and MMP-14 have been observed in the
more invasive and metastatic tumors [33]. Moreover,
overexpression of RhoA-GTP induces MMP expression
and activity [34]. We observed that statins significantly
inhibit the mRNA expression and enzymatic activities of
MMP-1, MMP-2, MMP-9, and MMP-14 in B16BL6
cells. These results suggest that the decrease in the acti-
vation of Rho is vital for the suppression of MMP
expressions by statins in B16BL6 cells.
Cell adhesion is a fundamental cellular response that is
intricately involved in the physiological processes of pro-
liferation, motility, as well as the pathology of neoplastic
transformation and metastasis. Integrins are the most
important family of cell surface adhesion molecules that
mediate interactions between cells and the ECM. Mem-
bers of the b1 integrin subfamily are known to primarily
bind to collagens, fibronectins, and laminins. We found
that statins suppress cell adhesion to type I collagen, type
IV collagen, fibronectin, and laminin. Furthermore, sta-
tins significantly inhibited the mRNA and protein expres-
sions of integrin a2, integrin a4, and integrin a5. A recent
study has reported that the activation of small GTPases
increased cell adhesion to collagens, fibronectins, and
laminins [35]. These findings indicate that the Rho/
ROCK pathway may be essential for the expressions of
integrin a2, integrin a4, and integrin a5.
Activation of Rho could lead to the activation of
LIMK and MLC [36]. These signal transduction factors
are essential for cell migration, invasion, adhesion, and
metastasis [37-39]. Our results clearly demonstrate that
statins induced a decrease in the phosphorylation of
LIMK and MLC. Moreover, we observed that Y27632, a
ROCK inhibitor, inhibited tumor cell metastasis through
suppressing LIMK and MLC activation. We previous
reported that Y27632 suppresses tumor cell migration,
invasion, and adhesion, as well as the expressions of
MMPs and integrins in B16BL6 cells, and then Y27632
did not show cytotoxic effect on B16BL6 cells [40].
MMP expressions can be induced by various growth
factors and cytokines, including epidermal growth factor
[41]. The expression of integrins can also be induced by
tumor necrosis factor alpha [42]. These inductions
require the activation of the Rho pathway. Therefore,
our present findings suggest that statins inhibit the
expression of MMPs and integrins by suppressing the
Rho/ROCK pathways.
Figure 5 Inhibitory effect of oral administration of statins on
lung metastasis. B16BL6 cells were injected into the tail veins of
syngeneic C57BL/6J mice. Mice were treated daily from days 1 to 14
with 10 mg/kg fluvastatin or simvastatin. After 14 d, visible nodules
that had metastasized to the lungs were counted. The results are
expressed as the mean ± SD for 9 mice.
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ponents are potential therapeutic targets for tumor pro-
gression and metastasis [43]. Farina et al. have reported
that lovastatin inhibits Rho isoprenylation, migration,
and metastasis in mouse mammary carcinoma cells [44].
Horiguchi et al. have also indicated that fluvastatin inhi-
bits invasion, angiogenesis, and metastasis in renal can-
cers [24]. However, no detailed data have been reported
on the exact mechanisms of the inhibitory effects of sta-
tins on the migration, invasion and metastasis of tumor
cells. In this study, we have indicated that the inhibitory
effect of statins on tumor cell migration, invasion, adhe-
sion, and metastasis suppresses the expression of MMPs
and integrins through inhibition of the Rho/ROCK path-
way. These findings indicate that Rho inhibitors, such as
statins, are appropriate age n t sf o rm o l e c u l a rt h e r a p i e s
against malignant tumor cells.
In the present study, the treatment of B16BL6 cells
with 0.05 μM fluvastatin or 0.1 μM simvastatin for 3 days
in vitro. The peak plasma concentrations of fluvastatin or
simvastatin achieved with standard doses were ≤1 μMo r
2.7 μM, respectively [24,45]. These findings indicate that
0.05 μMa n d0 . 1μM of fluvastatin and simvastatin,
respectively, are within the peak plasma values of fluvas-
tatin or simvastatin that are likely to be achieved in vivo.
We also observed that statins inhibit lung metastasis
when administered orally. Fluvastatin or simvastatin are
usually administered orally at daily doses of 20 to 80 mg
or 5 to 40 mg in patients with hypercholesterolemia.
Importantly, the dosage of statins orally administered to
patients with hypercholesterolemia would have prophy-
lactic effects against metastasis. This data indicates that
statins may be therapeutically useful for the treatment
of a variety of tumors.
Conclusion
In conclusion, our data show that statins inhibit tumor
cell migration, invasion, adhesion, and metastasis
through the suppression of the Rho/ROCK pathway.
These findings suggest that statins are potentially useful
as anti-metastatic agents for the treatment of melanoma.
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